AnaptysBio Inc
NASDAQ:ANAB
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
12.375
44.51
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
AnaptysBio Inc
Total Liabilities
AnaptysBio Inc
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
AnaptysBio Inc
NASDAQ:ANAB
|
Total Liabilities
$382.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
73%
|
CAGR 10-Years
38%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Liabilities
$136.5B
|
CAGR 3-Years
3%
|
CAGR 5-Years
0%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Liabilities
$37.1B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Liabilities
$80.5B
|
CAGR 3-Years
10%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Liabilities
$7.5B
|
CAGR 3-Years
27%
|
CAGR 5-Years
19%
|
CAGR 10-Years
17%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Liabilities
$9.2B
|
CAGR 3-Years
14%
|
CAGR 5-Years
9%
|
CAGR 10-Years
17%
|
|
AnaptysBio Inc
Glance View
AnaptysBio, Inc. is a clinical stage biotechnology company. The company is headquartered in San Diego, California and currently employs 102 full-time employees. The company went IPO on 2017-01-26. The firm is focused on the immune control mechanisms applicable to inflammation and immuno-oncology indications. The company develops products using antibody discovery technology platform, which is based upon a natural process of antibody generation, known as somatic hypermutation, and replicates this natural process of antibody generation in vitro. Its advanced antibody programs include: Imsidolimab is an antibody that inhibits the interleukin-36 receptor, for the treatment of inflammatory diseases called generalized pustular psoriasis and hidradenitis suppurativa; Rosnilimab is an anti-PD-1 agonist antibody program, is designed to augment PD-1 signaling through Rosnilimab treatment to suppress T-cell driven human inflammatory diseases; anti-BTLA modulator antibody, known as ANB032, is applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation.
See Also
What is AnaptysBio Inc's Total Liabilities?
Total Liabilities
382.5m
USD
Based on the financial report for Sep 30, 2025, AnaptysBio Inc's Total Liabilities amounts to 382.5m USD.
What is AnaptysBio Inc's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
38%
Over the last year, the Total Liabilities growth was -6%. The average annual Total Liabilities growth rates for AnaptysBio Inc have been 4% over the past three years , 73% over the past five years , and 38% over the past ten years .